Cancer immunotherapy in patients with brain metastases

被引：16

作者：

Caponnetto, Salvatore ^{[1
,2
,3
]}

Draghi, Arianna ^{[4
]}

Borch, Troels Holz ^{[4
,5
]}

Nuti, Marianna ^{[3
]}

Cortesi, Enrico ^{[1
,2
]}

Svane, Inge Marie ^{[4
,5
]}

Donia, Marco ^{[4
,5
]}

机构：

[1] Sapienza Univ Rome, Policlin Umberto 1, Dept Expt Med, Cell Therapy Unit, Rome, Italy

[2] Sapienza Univ Rome, Policlin Umberto 1, Dept Expt Med, Lab Tumor Immunol, Rome, Italy

[3] Sapienza Univ Rome, Policlin Umberto 1, Dept Radiol Oncol & Pathol Sci, Div Med Oncol B, Rome, Italy

[4] Univ Copenhagen, Herlev Hosp, Dept Hematol, CCIT, Herlev Ringvej 75, DK-2730 Herlev, Denmark

[5] Univ Copenhagen, Herlev Hosp, Dept Oncol, Herlev, Denmark

来源：

CANCER IMMUNOLOGY IMMUNOTHERAPY | 2018年 / 67卷 / 05期

关键词：

Cancer immunotherapy; Brain metastases; Check-point inhibitors; Ipilimumab; Nivolumab; Pembrolizumab; CELL LUNG-CANCER; OPEN-LABEL; RADIATION-THERAPY; ADVANCED MELANOMA; CLINICAL ACTIVITY; SINGLE-ARM; NIVOLUMAB; IPILIMUMAB; SAFETY; TREMELIMUMAB;

D O I：

10.1007/s00262-018-2146-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The exclusion of "real-world" patients from registration clinical trials of cancer immunotherapy represents a significant emerging issue. For instance, a large fraction of cancer patients develops brain metastases during the course of the disease, but results from large prospective clinical trials investigating this considerable proportion of the cancer patient population are currently lacking. To provide a useful tool for the clinician in a "real-world" setting, we have reviewed the available literature regarding the safety and efficacy of immune check-point inhibitors in patients with cancer metastatic to the brain. Overall, these data provide encouraging evidence that these therapeutic agents can induce intracranial objective responses, particularly in patients with asymptomatic and previously untreated brain metastases. Larger prospective studies are needed to confirm these initial results.

引用

页码：703 / 711

页数：9